By Myles Starr
As of late 2023, the federal government began to transition away from paying for COVID-19 drugs for privately insured Americans. Despite that shift in coverage, the Department of Health and Human Services (HHS) has announced that it will work with pharmacies, insurers and health systems to make sure that all Americans retain equitable access to COVID-19 therapies.
“No patient should be forced to pay the full out-of-pocket cost to access Paxlovid [nirmatrelvir+ritonavir,